StockNews.AI
LSTA
StockNews.AI
166 days

Lisata Therapeutics to Present at the Investival Showcase USA

1. Lisata Therapeutics CEO will present at Investival Showcase USA on March 11. 2. Company focuses on innovative therapies for advanced solid tumors and serious diseases. 3. Certepetide, their investigational drug, enables targeted penetration of solid tumors. 4. Lisata plans to announce significant milestones over the next 1.5 years. 5. Company's funding is projected to last into Q2 2026.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming presentation and expected milestones indicate positive momentum and potential interest from investors.

How important is it?

The article discusses key presentations and expected milestones that can directly influence investor sentiment and stock performance.

Why Short Term?

Immediate attention from investors due to the upcoming showcase may lead to short-term price movement.

Related Companies

NVIDIAPTCTPFE
March 06, 2025 08:30 ET  | Source: Lisata Therapeutics, Inc. BASKING RIDGE, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate overview at the Investival Showcase USA, taking place March 10-11, 2025 in Miami, Florida. Dr. Mazzo’s presentation is scheduled for Tuesday, March 11th at 11:30 a.m. Eastern Time. For more information about the conference, including registration details, please click here. About Lisata Therapeutics Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the second quarter of 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com. Lisata Therapeutics Contact: Investors:Lisata TherapeuticsJohn MendittoVice President, Investor Relations and Corporate CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com Media:ICR HealthcareElizabeth ColemanAccount SupervisorPhone: 203-682-4783Email: elizabeth.coleman@icrhealthcare.com This press release was published by a CLEAR® Verified individual.

Related News